Kanrenol

Potassium canrenoate, the active ingredient in Kanrenol, is an aldosterone antagonist presented as an injectable solution for intravenous use. It is employed to manage fluid retention, high blood pressure, and cardiac overload in adult patients. GNH USA supplies Kanrenol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kanrenol (potassium canrenoate) is indicated for conditions where aldosterone blockade helps control fluid balance and vascular resistance.

Heart failure: reduces cardiac preload and improves symptoms by promoting sodium excretion. Hypertension: lowers blood pressure through natriuresis and potassium retention. Edema: alleviates peripheral and pulmonary fluid accumulation by enhancing diuresis.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hyperkalemia: elevated serum potassium levels. - Hyponatremia: low sodium concentration in blood. - Dizziness or light‑headedness. - Headache. - Fatigue or weakness. - Gastrointestinal discomfort such as nausea.

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia. - Acute renal failure or worsening kidney function. - Anaphylactic or severe hypersensitivity reaction. - Hepatic dysfunction or jaundice. - Marked hypotension causing syncope. - Life‑threatening arrhythmias.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters.

Monitor electrolytes: check serum potassium and sodium regularly. Assess renal function: evaluate creatinine and glomerular filtration rate. Avoid in hyperkalemia: do not use when serum potassium is already elevated. Caution in hepatic impairment: adjust use if liver disease is present. Elderly patients: start with lower doses and monitor closely. Store at ambient temperature: keep in original container, protect from light and moisture.

Potential drug‑drug interactions should be reviewed to minimise adverse outcomes.

Major Interactions (Avoid): - ACE inhibitors or ARBs: combined use may cause dangerous hyperkalemia. - Potassium supplements or potassium‑sparing diuretics: increase risk of hyperkalemia. - NSAIDs: may impair renal clearance and exacerbate electrolyte disturbances. - Other aldosterone antagonists: additive effect on potassium levels. - Cyclosporine: can raise potassium concentrations.

Moderate Interactions (Monitor Closely): - Loop or thiazide diuretics: may alter electrolyte balance. - Digoxin: potassium changes can affect digoxin toxicity. - Lithium: altered renal handling may increase lithium levels. - Beta‑blockers: monitor blood pressure and heart rate. - Antidiabetic agents: fluid shifts may affect glucose control.